Agilent announces the appointment of Padraig McDonnell as CEO-elect and chief operating officer (COO), succeeding the incumbent President and CEO, Mike McMullen.
In a move poised to shape the future trajectory of Agilent Technologies Inc. (NYSE: A), the company has announced the appointment of Padraig McDonnell as CEO-elect and chief operating officer (COO), succeeding the incumbent President and CEO, Mike McMullen, who will retire. This significant leadership transition marks a pivotal moment for the well-known analytical and clinical laboratory technologies giant, headquartered in Santa Clara, California.
McDonnell, who is currently serving as the president of the Agilent CrossLab Group (ACG), will assume the role of president and CEO and join Agilent’s Board of Directors, effective May 1st. With nearly 40 years of dedicated service to Agilent and its predecessor Hewlett-Packard Co., McMullen will continue to serve as CEO and board member until the transition date. Subsequently, he will transition into an advisory role until his retirement on October 31st.
Koh Boon Hwee, chairman of Agilent’s Board of Directors, expressed confidence in McDonnell's capabilities, citing his successful tenure within Agilent. McDonnell has spearheaded exceptional growth in Agilent’s Services business and played a pivotal role in enhancing our customer’s experience, solidifying his reputation as a transformative leader within the organization.
McDonnell's ascent to the CEO role underscores Agilent’s commitment to continuity and growth. His extensive industry experience, coupled with a proven track record of driving innovation and profitability, positions him as a natural successor to McMullen. Under McMullen's leadership since 2015, Agilent witnessed substantial market capitalization growth, a testament to his strategic vision and operational prowess.
Reflecting on his forthcoming role, McDonnell expressed enthusiasm for the opportunity to lead Agilent into its next phase of development. He acknowledged McMullen’s mentorship and pledged to uphold Agilent’s legacy of innovation and customer-centricity.
Amidst these changes, Angelica Riemann will assume the role of ACG president, while Jonah Kirkwood will step into the position of chief commercial officer. Both will report directly to McDonnell, underscoring Agilent’s commitment to fostering internal talent and organizational continuity.
As Agilent embarks on this new chapter, McDonnell envisions a future brimming with possibilities and opportunities to further empower customers in their scientific achievements.
This article was written with the help of artificial intelligence and has been edited to ensure accuracy and clarity. You can read more about our policy for using AI here.
(1) Agilent Newsroom Home Page. https://www.agilent.com/about/newsroom/presrel/2024/21feb-gp24006.html (accessed 2024-02-26).
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
GPCRs – The Biological Traffic Modulator: Chromatographic Analysis of Peptides in the GI Tract
January 20th 2025The G protein-coupled receptors (GPCR) are found throughout the entire body and have shown significance in the development of new therapeutic treatments. Isolation of seven classic GRPC peptides initiating in the GI tract highlights the benefits of using the polymer-based PRP-3, a reversed-phase resin. The covalent bonds found in the PRP-3 exhibit advantageous interactions between the biological π bonds found in the peptides and the available aromatic benzyl rings of the resin.